Journal of Medicinal Chemistry
Article
muscle glucose metabolism. Evidence for a defect in hepatic
glucokinase activity. Diabetes 2000, 49, 272−283.
(28) For an example, seethe following: Torres, T. P.; Catlin, R. L.;
Chan, R.; Fujimoto, Y.; Sasaki, N.; Printz, R. L.; Newgard, C. B.;
Shiota, M. Restoration of hepatic glucokinase expression corrects
hepatic glucose flux and normalizes plasma glucose in Zucker diabetic
fatty rats. Diabetes 2009, 58, 78−86.
receptor modulator-statin hybrids. Bioorg. Med. Chem. Lett. 2004, 14,
4173−4178.
(32) Boyer, S. H.; Jiang, H.; Jacintho, J. D.; Reddy, M. V.; Li, H.;
Godwin, J. L.; Schulz, W. G.; Cable, E. E.; Hou, J.; Wu, R.; Fujitaki, J.
M.; Hecker, S. J.; Erion, M. D. Synthesis and biological evaluation of a
series of liver-selective phosphonic acid thyroid hormone receptor
agonists and their prodrugs. J. Med. Chem. 2008, 51, 7075−7093.
(33) For a review, seethe following: Erion, M. D.; Bullough, D. A.;
Lin, C.-C.; Hong, Z. HepDirect prodrugs for targeting nucleotide-
based antiviral drugs to the liver. Curr. Opin. Invest. Drugs 2006, 7,
109−117.
(29) (a) Pfefferkorn, J. A.; Litchfield, J.; Hutchings, R.; Cheng, X.-M.;
Larsen, S. D.; Auerbach, B.; Bush, M. R.; Lee, C.; Erasga, N.; Bowles,
D. M.; Boyles, D. C.; Lu, G.; Sekerke, C.; Askew, V.; Hanselman, J. C.;
Dillon, L.; Lin, Z.; Robertson, A.; Olsen, K.; Boustany, C.; Atkinson,
K.; Goosen, T. C.; Sahasrabudhe, V.; Chupka, J.; Duignan, D. B.; Feng,
B.; Scialis, R.; Kimoto, E.; Bi, Y.-A.; Lai, Y.; El-Kattan, A.; Bakker-
Arkema, R.; Barclay, P.; Kindt, E.; Le, V.; Mandema, J. W.; Milad, M.;
Tait, B. D.; Kennedy, R.; Trivedi, B. K.; Kowala, M. Discovery of novel
hepatoselective HMG-CoA reductase inhibitors for treating hyper-
cholesterolemia: a bench-to-bedside case study on tissue selective drug
distribution. Bioorg. Med. Chem. Lett. 2011, 21, 2725−2731.
(b) Ahmad, S.; Madsen, C. S.; Stein, P. D.; Janovitz, E.; Huang, C.;
Ngu, K.; Bisaha, S.; Kennedy, L. J.; Chen, B. C.; Zhao, R.; Sitkoff, D.;
Monshizadegan, H.; Yin, X.; Ryan, C. S.; Zhang, R.; Giancarli, M.;
Bird, E.; Chang, M.; Chen, X.; Setters, R.; Search, D.; Zhuang, S.;
Nguyen-Tran, V.; Cuff, C. A.; Harrity, T.; Darienzo, C. J.; Li, T.;
Reeves, R. A.; Blanar, M. A.; Barrish, J. C.; Zahler, R.; Robl, J. A.
(3R,5S,E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1H-
1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic
acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-
3-methylglutaryl coenzyme-A reductase inhibitor with reduced
myotoxicity potential. J. Med. Chem. 2008, 51, 2722−2733.
(c) Pfefferkorn, J. A.; Choi, C.; Larsen, S. D.; Auerbach, B.;
Hutchings, R.; Park, W.; Askew, V.; Dillon, L.; Hanselman, J. C.;
Lin, Z.; Lu, G. H.; Robertson, A.; Sekerke, C.; Harris, M. S.; Pavlovsky,
A.; Bainbridge, G.; Caspers, N.; Kowala, M.; Tait, B. D. Substituted
pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery
of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcar-
bamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334)
as a candidate for the treatment of hypercholesterolemia. J. Med. Chem.
2008, 51, 31−45.
(30) (a) Oballa, R. M.; Belair, L.; Black, W. C.; Bleasby, K.; Chan, C.
C.; Desroches, C.; Du, X.; Gordon, R.; Guay, J.; Guiral, S.; Hafey, M.
J.; Hamelin, E.; Huang, Z.; Kennedy, B.; Lachance, N.; Landry, F.; Li,
C. S.; Mancini, J.; Normandin, D.; Pocai, A.; Powell, D. A.; Ramtohul,
Y. K.; Skorey, K.; Sorensen, D.; Sturkenboom, W.; Styhler, A.;
Waddleton, D. M.; Wang, H.; Wong, S.; Xu, L.; Zhang, L.
Development of a liver-targeted stearoyl-CoA desaturase (SCD)
inhibitor (MK-8245) to establish a therapeutic window for the
treatment of diabetes and dyslipidemia. J. Med. Chem. 2011, 54, 5082−
5096. (b) Koltun, D. O.; Zilbershtein, T. M.; Migulin, V. A.;
Vasilevich, N. I.; Parkhill, E. Q.; Glushkov, A. I.; McGregor, M. J.;
Brunn, S. A.; Chu, N.; Hao, J.; Mollova, N.; Leung, K.; Chisholm, J.
W.; Zablocki, J. Potent, orally bioavailable, liver-selective stearoyl-CoA
desaturase (SCD) inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 4070−
4074. (c) Leclerc, J.-P.; Falgueyret, J.-P.; Girardin, M.; Guay, J.; Guiral,
S.; Huang, Z.; Li, C. S.; Oballa, R.; Ramtohul, Y. K.; Skorey, K.; Tawa,
P.; Wang, H.; Zhang, L. Conversion of systemically-distributed
triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-
targeted SCD inhibitors. Bioorg. Med. Chem. Lett. 2011, 21, 6505−
6509.
(34) Hoglen, N. C.; Chen, L.-S.; Fisher, C. D.; Hirakawa, B. P.;
Groessl, T.; Contreras, P. C. Characterization of IDN-6556 (3-{2-(2-
tert-butyl-phenylaminooxalyl)-amino]-propionylamino}-4-oxo-5-
(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase
inhibitor. J. Pharmacol. Exp. Ther. 2004, 309, 634−640.
́
(35) Boyer, S. H.; Sun, Z.; Jiang, H.; Esterbrook, J.; Gomez-Galeno, J.
E.; Craigo, W.; Reddy, K. R.; Ugarkar, B. G.; MacKenna, D. A.; Erion,
M. D. Synthesis and characterization of a novel cyclic 1-aryl-1,3-
propanyl prodrug of cytarabine monophosphate (MB07133) for the
treatment of hepatocellular carcinoma. J. Med. Chem. 2006, 49, 7711−
7720.
(36) Brocklehurst, K. J.; Payne, V. A.; Davies, R. A.; Carroll, D.;
Vertigan, H. L.; Wightman, H. J.; Aiston, S.; Waddell, I. D.; Leighton,
B.; Coghlan, M. P.; Agius, L. Stimulation of hepatocyte glucose
metabolism by novel small molecule glucokinase activators. Diabetes
2004, 53, 535−541.
(37) Segel, I. H. Enzyme Kinetics: Behavior and Analysis of Rapid
Equilibrium and Steady State Enzyme Systems; Wiley: New York, 1993.
(38) Kalgutkar, A. S.; Feng, B.; Nguyen, H. T.; Frederick, K. S.;
Campbell, S. D.; Hatch, H. L.; Bi, Y. A.; Kazolias, D. C.; Davidson, R.
E.; Mireles, R. J.; Duignan, D. B.; Choo, E. F.; Zhao, S. X. Role of
transporters in the disposition of the selective phosphodiesterase-4
inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbon-
yl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and
human. Drug Metab. Dispos. 2007, 35, 2111−2118.
(39) Di, L.; Whitney-Pickett, C.; Umland, J. P.; Zhang, H.; Zhang, X.;
Gebhard, D. F.; Lai, Y.; Federico, J. J.; Davidson, R. E.; Smith, R.;
Reyner, E. L.; Lee, C.; Feng, B.; Rotter, C.; Varma, M. V.; Kempshall,
S.; Fenner, K.; El-Kattan, A. F.; Liston, T. E.; Troutman, M. D.
Development of a new permeability assay using low-efflux MDCKII
cells. J. Pharm. Sci. 2011, 100, 4974−4985.
(40) (a) Cryle, M. J.; Matovic, N. J.; De Voss, J. J. Products of
cytochrome P450BioI (CYP107H1)-catalyzed oxidation of fatty acids.
Org. Lett. 2003, 5, 3341−3344. (b) Larcheveque, M.; Petit, Y. A simple
preparation of R or S glycidic esters; application to the synthesis of
enantiomerically pure α-hydroxyesters. Tetrahedron Lett. 1987, 28,
1993−1996.
(41) Pfefferkorn, J. A.; Lou, J.; Minich, M. L.; Filipski, K. J.; He, M.;
Zhou, R.; Ahmed, S.; Benbow, J.; Guzman-Perez, A.; Tu, M.;
Litchfield, J.; Sharma, R.; Metzler, K.; Bourbonais, F.; Huang, C.;
Beebe, D.; Oates, P. J. Pyridones as glucokinase activators:
identification of a unique metabolic liability of the 4-sulfonyl-2-
pyridone heterocycle. Bioorg. Med. Chem. Lett. 2009, 19, 3247−3252.
(42) For other representative examples where structure-based
structure strategies have utilized solvent exposed pockets to modulate
molecular properties, see the following: (a) Sun, L.; Liang, C.;
Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J. Y.; Chu, J.-Y.;
Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T. C.; Tang, F.;
Wei, J.; Tang, C. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-
(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-
diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting
vascular endothelial and platelet-derived growth factor receptor
tyrosine kinase. J. Med. Chem. 2003, 46, 1116−1119. (b) Plantan, I.;
Selic, L.; Mesar, T.; Stefanic Anderluh, P.; Oblak, M.; Prezelj, A.;
Hesse, L.; Andrejasic, M.; Vilar, M.; Turk, D.; Kocijan, A.; Prevec, T.;
Vilfan, G.; Kocjan, D.; Copar, A.; Urleb, U.; Solmajer, T. 4-Substituted
trinems as broad spectrum β-lactamase inhibitors: structure-based
(31) (a) von Geldern, T. W.; Tu, N.; Kym, P. R.; Link, J. T.; Jae, H.-
S.; Lai, C.; Apelqvist, T.; Rhonnstad, P.; Hagberg, L.; Koehler, K.;
̈
Grynfarb, M.; Goos-Nilsson, A.; Sandberg, J.; Osterlund, M.; Barkhem,
T.; Hoglund, M; Wang, J.; Fung, S.; Wilcox, D.; Nguyen, P.; Jakob, C.;
̈
̈
Hutchins, C.; Farnegardh, M.; Kauppi, B.; Ohman, L.; Jacobson, P. B.
̈
Liver-selective glucocorticoid antagonists: a novel treatment for type 2
diabetes. J. Med. Chem. 2004, 47, 4213−4230. (b) Link, J. T.;
Sorensen, B. K.; Lai, C.; Wang, J.; Fung, S.; Deng, D.; Emery, M.;
Carroll, S.; Grynfarb, M.; Goos-Nilson, A.; von Geldern, T. Synthesis,
activity, metabolic stability, and pharmacokinetics of glucocorticoid
1332
dx.doi.org/10.1021/jm2014887 | J. Med. Chem. 2012, 55, 1318−1333